Medical financial hardship among cancer survivors in the United States

Cancer

Volumn 125, Issue 10, 2019, Pages 1737-1747

  Zheng, Zhiyuan ^a   Jemal, Ahmedin ^a   Han, Xuesong ^a   Guy, Gery P ^b   Li, Chunyu ^b   Davidoff, Amy J ^c   Banegas, Matthew P ^d   Ekwueme, Donatus U ^b   Yabroff, K Robin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c YALE UNIVERSITY   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

benefit design; cancer survivors; health insurance; medical financial hardship

Indexed keywords

ADULT; ARTICLE; BANK ACCOUNT; CANCER SURVIVAL; CANCER SURVIVOR; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HEALTH INSURANCE; HUMAN; HUMAN EXPERIMENT; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PUBLIC HEALTH; UNITED STATES; YOUNG ADULT; AGE; AGED; COMPARATIVE STUDY; COST OF ILLNESS; CROSS-SECTIONAL STUDY; ECONOMICS; HEALTH CARE COST; RETROSPECTIVE STUDY; RISK ASSESSMENT; SOCIOECONOMICS; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CANCER SURVIVORS; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT, HEALTH CARE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SOCIOECONOMIC FACTORS; UNITED STATES; YOUNG ADULT;

EID: 85060329543     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.31913     Document Type: Article

References (54)

1. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271-289.
2. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20:2006-2014.
3. Bernard DS, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011;29:2821-2826.
4. Yabroff KR, Dowling EC, Guy GP, et al. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016;34:259-267.
5. Ekwueme DU, Yabroff KR, Guy GP Jr, et al. Centers for Disease Control and Prevention (CDC). Medical costs and productivity losses of cancer survivors–United States, 2008–2011. MMWR Morbid Mortal Wkly Rep. 2014;63:505-510.
6. Guy GP Jr, Ekwueme DU, Yabroff KR, et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol. 2013;31:3749-3757.
7. Zheng Z, Yabroff KR, Guy GP, et al. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. J Natl Cancer Inst. 2016;108(5).
8. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117-128.
9. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium—the just price. J Clin Oncol. 2013;31:3600-3604.
10. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439-4442.
11. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139-162.
12. Memorial Sloan Kettering Cancer Center. Price & Value of Cancer Drug. https://www.mskcc.org/research-areas/programs-centers/health-policy-outcomes/cost-drugs. Accessed March 2016.
13. Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract. 2010;6:301-307.
14. Henry J. Kaiser Family Foundation. 2014 Employer Health Benefits Survey. https://www.kff.org/health-costs/report/2014-employer-health-benefits-survey/. Accessed November 16, 2018.
15. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32:306-311.
16. Nekhlyudov L, Madden J, Graves A, Zhang F, Soumerai S, Ross-Degnan D. Cost-related medication nonadherence and cost-saving strategies used by elderly Medicare cancer survivors. J Cancer Surviv. 2011;5:395-404.
17. Weaver KE, Rowland JH, Bellizzi KM, Aziz NM. Forgoing medical care because of cost: assessing disparities in health care access among cancer survivors living in the United States. Cancer. 2010;116:3493-3504.
18. Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32:1143-1152.
19. Banegas MP, Guy GP Jr, de Moor JS, et al. For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff (Millwood). 2016;35:54-61.
20. Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34:980-986.
21. Zafar SY. Financial toxicity of cancer care: it's time to intervene. J Natl Cancer Inst. 2016;108(5).
22. Tucker-Seeley RD, Abel GA, Uno H, Prigerson H. Financial hardship and the intensity of medical care received near death. Psychooncology. 2015;24:572-578.
23. Kent EE, Forsythe LP, Yabroff KR, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119:3710-3717.
24. Yabroff KR, Zhao J, Zheng Z, Rai A, Han X. Medical financial hardship among cancer survivors in the United States: what do we know? What do we need to know? [published online ahead of print November 14, 2018]. Cancer Epidemiol Biomarkers Prev. https://doi.org/10.1158/1055-9965.EPI-18-0617.
25. Health Policy Brief: High-Deductible Health Plans. Health Affairs Blog. February 5, 2016. https://doi.org/10.1377/hblog20160205.053022.
26. Gabel J, Whitmore H, Call A, Green M, Oran R, Stromberg S. Modest Changes in 2016 Health Insurance Marketplace Premiums and Insurer Participation. The Commonwealth Fund Blog. January 27, 2016.
27. National Center for Health Statistics. Survey Description, National Health Interview Survey, 2017. Hyattsville, MD: National Center for Health Statistics; 2017.
28. White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(3 Suppl 1):S7-S15.
29. National Center for Health Statistics. Health, United States, 2014. Washington, DC: Department of Health and Human Services; 2015.
30. Zheng Z, Han X, Guy GP, et al. Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. Cancer. 2017;123:1453-1463.
31. Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2017;109(2).
32. Greene WH. Econometric Analysis. Chapter 21, Models for Discrete Choice. 7th ed. Boston: Pearson Education; 2012:719-722.
33. Ng AK, Travis LB. Second primary cancers: an overview. Hematol Oncol Clin North Am. 2008;22:271-289.
34. Oeffinger KC, Bhatia S. Second primary cancers in survivors of childhood cancer. Lancet. 2009;374:1484-1485.
35. Short PF, Moran JR, Punekar R. Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer. 2011;117:2791-2800.
36. Gonzales F, Zheng Z, Yabroff KR Trends in financial access to prescription drugs among cancer survivors. J Natl Cancer Inst. 2018;110(2).
37. Yabroff KR, Borowski L, Lipscomb J. Economic studies in colorectal cancer: challenges in measuring and comparing costs. J Natl Cancer Inst Monogr. 2013;2013:62-78.
38. Short PF, Vasey JJ, Belue R. Work disability associated with cancer survivorship and other chronic conditions. Psychooncology. 2008;17:91-97.
39. Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst. 2004;96:1322-1330.
40. Smith JC, Medalia C. Health Insurance Coverage in the United States: 2013. Washington, DC: US Census Bureau; 2014. Current Population Report No. P60–250.
41. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18:381-390.
42. HealthCare.gov. Certified Application Counselor. https://www.healthcare.gov/glossary/certified-applicant-counselor/. Accessed November 16, 2018.
43. Virgo KS, Bromberek JL, Glaser A, Horgan D, Maher J, Brawley OW. Health care policy and cancer survivorship. Cancer. 2013;119(suppl 11):2187-2199.
44. Henry J. Kaiser Family Foundation. The Coverage Provisions in the Affordable Care Act: An Update. https://www.kff.org/health-reform/issue-brief/the-coverage-provisions-in-the-affordable-care-act-an-update/. Accessed November 16, 2018.
45. Davidoff AJ, Guy GP Jr, Hu X, et al. Changes in health insurance coverage associated with the Affordable Care Act among adults with and without a cancer history: population-based national estimates. Med Care. 2018;56:220-227.
46. Cohen RA, Zammitti EP. Credible Statistics on the Financial Barriers of High-Deductible Health Plans: High-Deductible Health Plans and Financial Barriers to Medical Care: Early Release of Estimates From the National Health Interview Survey, 2016. http://pnhp.org/news/credible-statistics-on-the-financial-barriers-of-high-deductible-health-plans/. Accessed November 16, 2018.
47. Wharam JF, Zhang F, Lu CY, et al. Breast cancer diagnosis and treatment after high-deductible insurance enrollment. J Clin Oncol. 2018;36:1121-1127.
48. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30:91-99.
49. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology. American Society of Clinical Oncology Guidance Statement: the cost of cancer care. J Clin Oncol. 2009;27:3868-3874.
50. Shih YT, Chien CR. A review of cost communication in oncology: patient attitude, provider acceptance, and outcome assessment. Cancer. 2017;123:928-939.
51. Irwin B, Kimmick G, Altomare I, et al. Patient experience and attitudes toward addressing the cost of breast cancer care. Oncologist. 2014;19:1135-1140.
52. Bestvina CM, Zullig LL, Rushing C, et al. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014;10:162-167.
53. de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 2014;120:3245-3253.
54. Khera N. Reporting and grading financial toxicity. J Clin Oncol. 2014;32:3337-3338.